Tumour Regression via Integrative Regulation of Neurological, Inflammatory, and Hypoxic Tumour Microenvironment
Chang Hoon Lee*, Jungsook Cho and Kyeong Lee
College of Pharmacy, Dongguk University, Seoul 04620, Republic of Korea
*E-mail: uatheone@dongguk.edu
Tel: +82-31-961-5213, Fax: +82-31-961-5206
Received: August 15, 2019; Revised: October 5, 2019; Accepted: October 8, 2019; Published online: November 18, 2019.
© The Korean Society of Applied Pharmacology. All rights reserved.

Changing trends in anticancer research have altered the treatment paradigm to the extent that it is difficult to investigate any anticancer drugs without mentioning immunotherapy. Thus, we are finally contemplating tumour regression using magic bullets known as immunotherapy drugs. This review explores the possible options and pitfalls in tumour regression by first elucidating the features of cancer and the importance of tumour microenvironments. Next, we evaluated the trends of anticancer therapeutics regulating tumour microenvironment. Finally, we introduced the concept of tumour regression and various targets of tumour microenvironment, which can be used in combination with current immunotherapy for tumour regression. In particular, we emphasize the importance of regulating the neurological manifestations of tumour microenvironment (N) in addition to inflammation (I) and hypoxia (H) in cancer.
Keywords: Immunotherapy, Tumour regression, Tumour microenvironment, Neurological, Inflammation, Hypoxia

This Article

Cited By Articles
  • CrossRef (0)